Clinical Trials Logo
  1. Home
  2. Pancreatic Insufficiency
  3. NCT05466838

PERT to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial — PERQ-UP  

Pancreatic Insufficiency Clinical Trial

Official title:
Pancreatic Enzyme Replacement Therapy to Improve Quality of Life in Patients Undergoing Pancreaticoduodenectomy: A Pilot Randomized Controlled Trial

Clinical Trial Summary

After pancreas surgery, patients may develop pancreatic exocrine insufficiency (PEI). PEI can be treated with oral pancreatic enzyme replacement therapy (PERT). However, the diagnosis of PEI is difficult and the guidelines about when to start PERT after pancreas surgery are conflicting. This pilot study aims to determine the feasibility of implementing a large-scale clinical trial to definitively evaluate if starting PERT immediately after surgery can improve outcomes in patients undergoing pancreas surgery.

Clinical Trial Description

After pancreas surgery, patients may develop pancreatic exocrine insufficiency (PEI). This occurs when there are not enough exocrine cells in the pancreas to release enzymes that help with food digestion. Potential symptoms may include bloating, cramping, large and foul-smelling bowel movements (steatorrhea), and other gastrointestinal symptoms like diarrhea, weight-loss, and malnutrition. PEI can be treated with oral pancreatic enzyme replacement therapy (PERT), for example CREON. Many studies have shown that treatment of PEI with PERT is safe, effective, and may improve quality of life, reduce weight loss, improve abdominal symptoms, and may improve overall survival. However, the diagnosis of PEI is difficult and the guidelines about when to start PERT after pancreas surgery are conflicting. This pilot study aims to determine the feasibility of implementing a large-scale clinical trial to definitively evaluate if starting PERT immediately after surgery can improve outcomes in patients undergoing pancreas surgery. Participants will be recruited from Ontario hospitals using a two-step eligibility process (pre- and post-operatively) and randomized 1:1 to receive either standard of care or PERT plus standard of care. Outcome measures will be collected 1 and 3 months postoperatively. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05466838
Study type Interventional
Source Sunnybrook Health Sciences Centre
Contact Paul Karanicolas, MD, PhD
Phone 416-480-4774
Email Paul.karanicolas@sunnybrook.ca
Status Recruiting
Phase N/A
Start date January 6, 2023
Completion date August 31, 2024
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03279653 - Pancreatic Exocrine Insufficiency After Bariatric Surgery N/A
Completed NCT00763412 - Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis N/A
Recruiting NCT01851694 - Beta-cell Response to Incretin Hormones in Cystic Fibrosis N/A
Completed NCT01988350 - Pancreatic Insufficiency Secondary to Tobacco Exposure N/A
Completed NCT01710644 - Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis Phase 1/Phase 2
Active, not recruiting NCT01012908 - Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency Phase 2/Phase 3
Completed NCT01879228 - Effect of Chronic Incretin-based Therapy in Cystic Fibrosis N/A
Completed NCT00705978 - Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis Phase 3
Completed NCT00095732 - Oral TheraCLEC™ - Total in Cystic Fibrosis Subjects With Exocrine Pancreatic Insufficiency Phase 2
Completed NCT00513682 - Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI) Phase 3
Completed NCT02979340 - MRI to Characterize and Predict CF Liver Disease in PUSH Cohort
Completed NCT00406536 - Study of LYM-X-SORB™ to Improve Fatty Acid and Choline Status in Children With CF and PI Phase 2
Completed NCT00432861 - Evaluation of the Safety and Efficacy of Pancrecarb® MS-16 in Cystic Fibrosis Phase 3
Completed NCT01144507 - Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis
Completed NCT05700604 - Hypoglycemia and Glucagon Response in CF
Terminated NCT02985801 - PERT for Treatment of Exocrine Pancreatic Insufficiency in Patients With Unresectable Pancreatic Cancer Phase 1/Phase 2
Completed NCT03551691 - Proton Pump Inhibitors (PPI) and Fat Absorption in Cystic Fibrosis (CF) and Exocrine Pancreatic Insufficiency (EPI) Phase 2
Recruiting NCT03450772 - Equivalence Study to Compare Two Strengths of Creon in China Phase 3
Completed NCT00572975 - Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea Phase 4
Completed NCT00880100 - Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF) Phase 3